People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, ...

When it comes to medically assisted weight loss, there’s two main schools of thought: either weight loss drugs, like the ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

It appears an unintended side effect of the drug has now struck some of Britain's known suitmakers, who are fed up with ...

Research has found that GLP-1 receptors, found in medications like Wegovy and Monjaro, may offer health benefits beyond the ...

Two weeks into the job, it’s clear that newly elected State Treasurer Brad Briner won’t shy away from taking action, even if ...

New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

New diet drugs are making it easier to lose weight. So does that mean we can stop exercising? Health experts say no. There is ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...